Compare VTSI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | RNXT |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 42.4M |
| IPO Year | 1999 | 2021 |
| Metric | VTSI | RNXT |
|---|---|---|
| Price | $3.10 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $8.25 |
| AVG Volume (30 Days) | 38.9K | ★ 190.9K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $185,971.00 | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | $27.30 | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $2.88 | $0.70 |
| 52 Week High | $7.47 | $1.45 |
| Indicator | VTSI | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 58.73 |
| Support Level | $3.05 | $0.81 |
| Resistance Level | $3.60 | $0.98 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 59.46 | 93.27 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.